Antitumour Necrosis Factor-Α Agents and Development of New-Onset Cirrhosis or Non-Alcoholic Fatty Liver Disease: A Retrospective Cohort

BMJ Open Gastroenterology - United Kingdom
doi 10.1136/bmjgast-2019-000349
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Gut Microbiota and Non-Alcoholic Fatty Liver Disease: New Insights

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2013English

Non-Alcoholic Fatty Liver Disease and Disease Mongering

American Journal of Medicine
Medicine
2019English

Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatits in Patients With Childhood-Onset Adult Growth Hormone Deficiency

Clinical Pediatric Endocrinology
Child HealthEndocrinologyPerinatologyPediatricsMetabolismDiabetes
2005English

Review Article: New Treatments in Non-Alcoholic Fatty Liver Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Treatment of Non-Alcoholic Fatty Liver Disease

Postgraduate Medical Journal
Medicine
2006English

Global Perspectives on Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Hepatology
MedicineHepatology
2019English

Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease

2018English

Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD)

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Emerging New Standard for Non-Invasive Assessment of Liver Disease Mortality in Non-Alcoholic Fatty Liver Disease

HepatoBiliary Surgery and Nutrition
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy